Tauroursodeoxycholic acid is an investigational drug.
There have been 23 clinical trials for Tauroursodeoxycholic acid.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2012.
The most common disease conditions in clinical trials are Sclerosis, Motor Neuron Disease, and Amyotrophic Lateral Sclerosis. The leading clinical trial sponsors are Washington University School of Medicine, University of Dublin, Trinity College, and University of Sheffield.